{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"203.0"},{"groupId":"OG001","value":"215.0"},{"groupId":"OG002","value":"345.0"},{"groupId":"OG003","spread":"173","value":"509.7"},{"groupId":"OG004","spread":"65","value":"1148"},{"groupId":"OG005","spread":"117","value":"1782"},{"groupId":"OG006","spread":"309","value":"1309"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"4"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"222.0"},{"groupId":"OG001","value":"255.0"},{"groupId":"OG002","value":"618.0"},{"groupId":"OG003","spread":"85","value":"1050"},{"groupId":"OG004","spread":"131","value":"1787"},{"groupId":"OG005","spread":"98","value":"2727"},{"groupId":"OG006","spread":"88","value":"2917"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"15"},{"groupId":"OG006","value":"4"}],"units":"Participants"}],"title":"Cycle 1 Day 7"},{"categories":[{"measurements":[{"groupId":"OG000","value":"128.0"},{"groupId":"OG001","value":"240.0"},{"groupId":"OG002","value":"200.0"},{"groupId":"OG003","spread":"112","value":"696.0"},{"groupId":"OG004","spread":"158","value":"1019"},{"groupId":"OG005","spread":"95","value":"1876"},{"groupId":"OG006","spread":"137","value":"2434"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"4"}],"units":"Participants"}],"title":"Cycle 2 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"4"}],"units":"Participants"}],"description":"Cmax was directly observed from data. Cmax was defined as maximum observed plasma concentration.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"PF-06952229 was administered at a dose of 20 mg orally twice daily (BID) for 7 days on, 7 days off for each Cycle (one cycle = 28 days).","id":"OG000","title":"Part 1A: PF-06952229 20mg Monotherapy"},{"description":"PF-06952229 was administered at a dose of 40 mg orally BID for 7 days on, 7 days off for each Cycle (one cycle = 28 days).","id":"OG001","title":"Part 1A: PF-06952229 40mg Monotherapy"},{"description":"PF-06952229 was administered at a dose of 80 mg orally BID for 7 days on, 7 days off for each Cycle (one cycle = 28 days).","id":"OG002","title":"Part 1A: PF-06952229 80mg Monotherapy"},{"description":"PF-06952229 was administered at a dose of 150 mg orally BID for 7 days on, 7 days off for each Cycle (one cycle = 28 days).","id":"OG003","title":"Part 1A: PF-06952229 150mg Monotherapy"},{"description":"PF-06952229 was administered at a dose of 250 mg orally BID for 7 days on, 7 days off for each Cycle (one cycle = 28 days).","id":"OG004","title":"Part 1A: PF-06952229 250mg Monotherapy"},{"description":"PF-06952229 was administered at a dose of 375 mg orally BID for 7 days on, 7 days off for each Cycle (one cycle = 28 days).","id":"OG005","title":"Part 1A: PF-06952229 375mg Monotherapy"},{"description":"PF-06952229 was administered at a dose of 500 mg orally BID for 7 days on, 7 days off for each Cycle (one cycle = 28 days).","id":"OG006","title":"Part 1A: PF-06952229 500mg Monotherapy"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Participants with advanced/metastatic tumors in PF-06952229 single agent dose escalation phase, who had sufficient information to estimate at least 1 of the pharmacokinetic (PK) parameters of interest. Here, \"number analyzed\" signifies participant evaluable for each row.","reportingStatus":"POSTED","timeFrame":"0 (pre dose), 0.5, 1, 2, 4, 6 and 12 hours (post dose) on Day 1 and 7 of cycle 1, 0 (pre dose), 0.5, 1, 2, 4, 6 and 12 hours (post dose) on Day 1 of cycle 2.","title":"Maximum Observed Plasma Concentration (Cmax) of PF-06952229 (Part 1A)","type":"SECONDARY","unitOfMeasure":"nanograms/milliliter (ng/mL)"}